Zacks Investment Research Upgrades DiaMedica Therapeutics (NASDAQ:DMAC) to Hold

Zacks Investment Research upgraded shares of DiaMedica Therapeutics (NASDAQ:DMAC) from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports.

According to Zacks, “DiaMedica Therapeutics Inc. is a biopharmaceutical company. It engages in the development of novel recombinant proteins and monoclonal antibodies. The companys lead product principally consists DM199, a recombinant human tissue kallikrein-1 protein. It operates primarily in the United States and Canada. DiaMedica Therapeutics Inc. is headquartered in Minneapolis, Minnesota. “

Separately, ValuEngine downgraded shares of DiaMedica Therapeutics from a buy rating to a hold rating in a research note on Thursday, December 19th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company has a consensus rating of Buy and an average target price of $8.38.

Shares of NASDAQ:DMAC traded down $0.02 during midday trading on Wednesday, hitting $4.46. 800 shares of the stock were exchanged, compared to its average volume of 61,470. The company has a 50 day moving average price of $3.94 and a 200-day moving average price of $3.32. DiaMedica Therapeutics has a twelve month low of $1.70 and a twelve month high of $5.93. The company has a current ratio of 8.97, a quick ratio of 8.97 and a debt-to-equity ratio of 0.01.

DiaMedica Therapeutics (NASDAQ:DMAC) last announced its earnings results on Wednesday, November 13th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.01). On average, equities research analysts expect that DiaMedica Therapeutics will post -0.93 earnings per share for the current fiscal year.

Hedge funds have recently made changes to their positions in the stock. Millennium Management LLC boosted its holdings in DiaMedica Therapeutics by 54.6% in the 3rd quarter. Millennium Management LLC now owns 70,919 shares of the company’s stock valued at $145,000 after purchasing an additional 25,037 shares during the last quarter. Commonwealth Equity Services LLC acquired a new position in DiaMedica Therapeutics in the 3rd quarter valued at about $27,000. Worth Venture Partners LLC boosted its holdings in DiaMedica Therapeutics by 10.6% in the 2nd quarter. Worth Venture Partners LLC now owns 132,514 shares of the company’s stock valued at $657,000 after purchasing an additional 12,651 shares during the last quarter. Vanguard Group Inc. acquired a new position in DiaMedica Therapeutics in the 2nd quarter valued at about $170,000. Finally, BlackRock Inc. boosted its holdings in DiaMedica Therapeutics by 159.7% in the 2nd quarter. BlackRock Inc. now owns 27,075 shares of the company’s stock valued at $134,000 after purchasing an additional 16,651 shares during the last quarter. 8.01% of the stock is owned by hedge funds and other institutional investors.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications.

Recommended Story: How Do You Make Money With Penny Stocks?

Get a free copy of the Zacks research report on DiaMedica Therapeutics (DMAC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for DiaMedica Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DiaMedica Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.